Literature DB >> 31601470

Clinical application of Albumin-Bilirubin (ALBI) score: The current status.

Min Deng1, Sally Wing Yan Ng1, Siu Tim Cheung1, Charing Ching Ning Chong2.   

Abstract

Prognosis of patients that have undergone liver resection can be predicted preoperatively. Albumin-Bilirubin (ALBI) is a useful score to evaluate liver function objectively. This score is simple to use, uses objective parameters, and can stratify patients into grades. In combination with other liver cancer scores, the prognosis and survival of patients can be evaluated with more accuracy. Current literatures supporting the use of the ALBI score relating to prognosis of post hepatectomy, radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiotherapy and systemic therapy are available. Therefore, ALBI score is worthy of clinical application. The following is a review of the current literatures on the ALBI score.
Copyright © 2019 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ALBI; Liver function; Prognosis; Survival

Year:  2019        PMID： 31601470     DOI： 10.1016/j.surge.2019.09.002

Source DB:  PubMed          Journal:  Surgeon        ISSN： 1479-666X            Impact factor:   2.392


  8 in total

Review 1.  Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis.

Authors:  Gauri Mishra; Ammar Majeed; Anouk Dev; Guy D Eslick; David J Pinato; Hirofumi Izumoto; Atsushi Hiraoka; Teh-Ia Huo; Po-Hong Liu; Philip J Johnson; Stuart K Roberts
Journal:  J Gastrointest Cancer       Date:  2022-05-30

2.  Diabetes mellitus and postoperative blood glucose value help predict posthepatectomy liver failure in patients with hepatocellular carcinoma.

Authors:  Jianchen Luo; Liangliang Xu; Lian Li; Jingfu Zhang; Ming Zhang; Mingqing Xu
Journal:  J Gastrointest Oncol       Date:  2021-10

3.  Successful management and technical aspects of major liver resection in children: A retrospective cohort study.

Authors:  Kewei Li; Fanwen Jiang; Matthew Aizpuru; Ellen L Larson; Xiaolong Xie; Rongxing Zhou; Bo Xiang
Journal:  Medicine (Baltimore)       Date:  2021-02-12       Impact factor: 1.817

4.  Preoperative Predictors for 90-Day Mortality after Pancreaticoduodenectomy in Patients with Adenocarcinoma of the Ampulla of Vater: A Single-Centre Retrospective Cohort Study.

Authors:  Ramiro Fernandez-Placencia; Francisco Berrospi-Espinoza; Karla Uribe-Rivera; Jose Medina-Cana; Ivan Chavez-Passiuri; Nestor Sanchez-Bartra; Kori Paredes-Galvez; Carlos Luque-Vasquez Vasquez; Juan Celis-Zapata; Eloy Ruiz-Figueroa
Journal:  Surg Res Pract       Date:  2021-02-27

5.  Potential of Liver T1 Mapping for the Detection of Fontan-associated Liver Disease in Adults.

Authors:  Yumi Shiina; Kei Inai; Ryoko Ohashi; Michinobu Nagao
Journal:  Magn Reson Med Sci       Date:  2020-09-07       Impact factor: 2.471

6.  Albumin-Bilirubin Score to Predict Outcomes in Patients with Idiopathic Dilated Cardiomyopathy.

Authors:  Mei Jiang; Xue-Biao Wei; Jie-Leng Huang; Ze-da-Zhong Su; Ying-Wen Lin; Dan-Qing Yu
Journal:  Arq Bras Cardiol       Date:  2022-06-10       Impact factor: 2.667

7.  Predictive value of Albumin-Bilirubin grade for intravenous immunoglobulin resistance in a large cohort of patients with Kawasaki disease: a prospective study.

Authors:  Yu Yan; Lina Qiao; Yimin Hua; Shuran Shao; Nanjun Zhang; Mei Wu; Lei Liu; Kaiyu Zhou; Xiaoliang Liu; Chuan Wang
Journal:  Pediatr Rheumatol Online J       Date:  2021-09-25       Impact factor: 3.054

8.  Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy.

Authors:  Min Deng; Shaohua Li; Qiaoxuan Wang; Rongce Zhao; Jingwen Zou; Wenping Lin; Jie Mei; Wei Wei; Rongping Guo
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.